Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

Abstract:

INTRODUCTION:Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal inactivated influenza vaccines (IIVs) are currently under reconsideration as a promising intranasal influenza vaccine. AREAS COVERED:This review addresses the history of intranasal IIV research and development, along with a summary of the studies done so far to address the mechanism of action of intranasal IIVs. EXPERT COMMENTARY:From numerous in vitro and in vivo studies, it has been shown that intranasal IIVs can protect hosts from a broad spectrum of influenza virus strains. In-depth studies of the mucosal antibody response following intranasal IIV administration have also elucidated the detailed functions of secretory IgA (immunoglobulin A) antibodies which are responsible for the mechanism of action of intranasal vaccines. Safe and effective intranasal IIVs are expected to be an important tool to combat seasonal influenza.

journal_name

Expert Rev Vaccines

authors

Sano K,Ainai A,Suzuki T,Hasegawa H

doi

10.1080/14760584.2018.1507743

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

687-696

issue

8

eissn

1476-0584

issn

1744-8395

journal_volume

17

pub_type

杂志文章,评审
  • T-cell immunity generated by recombinant adenovirus vaccines.

    abstract::Recombinant adenovirus vaccines show great promise for generating protective immunity against infectious agents and tumors. Our studies have identified several interesting biological features of the adenovirus vector that influence the T-cell response. Notably, we have demonstrated that following immunization with ade...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.3.347

    authors: Yang TC,Millar JB,Grinshtein N,Bassett J,Finn J,Bramson JL

    更新日期:2007-06-01 00:00:00

  • Challenges of Global Vaccine Development.

    abstract::The Keystone Symposia conference, Challenges of Global Vaccine Development, attracted approximately 440 scientists, physicians and students from all around the world. The conference goal was to share newly acquired knowledge regarding vaccine-induced immunity, novel technologies, childhood vaccines, preclinical models...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/14760584.7.1.21

    authors: Gudmundsdotter L,Hallengärd D

    更新日期:2008-02-01 00:00:00

  • Controlling pertussis: how can we do it? A focus on immunization.

    abstract:INTRODUCTION:Pertussis is a highly contagious disease of the respiratory tract which is caused by the bacterium Bordetella pertussis and is most severe in those <1 year of age. A vaccine against pertussis, introduced in the 1950's, led to a significant decrease in incidence of the disease, but recent increases in outbr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1445530

    authors: Martinón-Torres F,Heininger U,Thomson A,Wirsing von König CH

    更新日期:2018-04-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00

  • DNA-launched live-attenuated vaccines for biodefense applications.

    abstract::A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1175943

    authors: Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

    更新日期:2016-09-01 00:00:00

  • Specific Lactobacillus species differentially activate Toll-like receptors and downstream signals in dendritic cells.

    abstract:BACKGROUND:Dendritic cells (DCs) regulate mucosal T-cell immunity and encounter several distinct bacteria of the gut flora, including lactobacilli. Gram-positive lactobacilli have been suggested to play an important role in exerting adjuvanticity effects on innate immune cells at mucosal sites. AIMS & METHODS:In the p...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.8.1155

    authors: Mohamadzadeh M,Klaenhammer TR

    更新日期:2008-10-01 00:00:00

  • Vaccine development for syphilis.

    abstract:INTRODUCTION:Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevent...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1203262

    authors: Lithgow KV,Cameron CE

    更新日期:2017-01-01 00:00:00

  • Peptidomimetics: modifying peptides in the pursuit of better vaccines.

    abstract::Peptide vaccines represent a potential strategy for the prevention and treatment of pathogenic diseases, cancers and autoimmune disorders; their low cost, ease of synthesis and inherent safety are all attractive features. However, they have remained largely unsuccessful owing to low immunogenicity, predominantly stemm...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.161

    authors: Croft NP,Purcell AW

    更新日期:2011-02-01 00:00:00

  • Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations.

    abstract::Introduction: Precision medicine describes the customization of healthcare tailored to the individual patient. Generally, vaccines are considered as public health tools rather than from the individual patient perspective. However, adult vaccination programs in particular should consider many different factors, at the ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1607303

    authors: Park SB,Kim HJ,Cheong HJ

    更新日期:2019-06-01 00:00:00

  • Vaccines and febrile seizures.

    abstract::Vaccine administration is the second leading cause of febrile seizures (FS). FS occurrence in children is a serious concern because it leads to public apprehension of vaccinations. This review discusses the clinical implications of FS, its potential link to vaccinations and its impact on official recommendations for v...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2013.814781

    authors: Principi N,Esposito S

    更新日期:2013-08-01 00:00:00

  • Improving vaccines by incorporating immunological coadjuvants.

    abstract::While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune respon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.4.559

    authors: Fraser CK,Diener KR,Brown MP,Hayball JD

    更新日期:2007-08-01 00:00:00

  • Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans.

    abstract::Protection against acquisition of fully heterologous, neutralization-resistant SIV was achieved in rhesus monkeys with adenovirus/poxvirus vector-based vaccines. Protection against acquisition of infection required the inclusion of envelope antigens and correlated with the induction of binding antibodies against the E...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.21

    authors: Esparza J

    更新日期:2012-05-01 00:00:00

  • Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.

    abstract::Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, differen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.862499

    authors: Talebian Yazdi M,Keene KR,Hiemstra PS,van der Burg SH

    更新日期:2014-01-01 00:00:00

  • Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.

    abstract::Efforts to develop a meningococcal vaccine that will include coverage against serogroup B disease have largely focused on outer membrane protein antigens. The protection offered by currently licensed outer membrane vesicle (OMV) vaccines is specific to epidemic strains as their immunodominant antigens are highly varia...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.10

    authors: Sanders H,Feavers IM

    更新日期:2011-03-01 00:00:00

  • Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data.

    abstract:INTRODUCTION:Meningococcal disease has an incidence peak spread over several years during adolescence and young adulthood in the United States. Meningococcal serogroup B (MenB) vaccines have been introduced relatively recently and may help protect individuals in these age groups. Currently there is insufficient long-te...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1580579

    authors: Watson PS,Novy P,Bekkat-Berkani R,Strubbe F,Banzhoff A

    更新日期:2019-04-01 00:00:00

  • Generating humoral immune memory following infection or vaccination.

    abstract::The production of long-lived, high-affinity antibodies forms the basis of many successful vaccination strategies. Although much is known of the proteins and pathways of the immune system that lead to the production of these antibodies, there are also many processes that remain unexplained or poorly explained. Some vac...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.103

    authors: Randall KL

    更新日期:2010-09-01 00:00:00

  • In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

    abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1599286

    authors: Berkhout A,Clark JE,Wen SC

    更新日期:2019-05-01 00:00:00

  • Recent advances in developing vaccines against Toxoplasma gondii: an update.

    abstract::Toxoplasma gondii, a significant public health risk, is able to infect almost all warm-blooded animals including humans, and it results in economic losses in production animals. In the last three years, a large number of vaccination experiments have been performed to control T. gondii infection, with the target of lim...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1098539

    authors: Zhang NZ,Wang M,Xu Y,Petersen E,Zhu XQ

    更新日期:2015-01-01 00:00:00

  • Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

    abstract::Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.9.1367

    authors: Dinleyici EC,Yargic ZA

    更新日期:2008-11-01 00:00:00

  • Vaccines: facing complex problems with the promise of immunology.

    abstract::Highly renowned in the vaccines world, Stanley A. Plotkin has worked at many leading institutions throughout his career, and is Emeritus Professor of the University of Pennsylvania and Adjunct Professor of the Johns Hopkins University. In 1991, Plotkin joined Sanofi Pasteur and worked there from 1991 to 1997, and now ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/14760584.2014.934678

    authors: Plotkin SA,Rees J

    更新日期:2014-08-01 00:00:00

  • Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.

    abstract:BACKGROUND:Viruses from two antigenically distinct influenza B strains have co-circulated since the mid-1980s, yet inactivated trivalent influenza vaccines (TIVs) with either the Victoria or Yamagata lineage could only provide limited protection from influenza B strain. Quadrivalent influenza vaccine (QIV) including bo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14760584.2017.1374181

    authors: Wang SY,Liu SZ,Chu K,Zhao Y,Zhu FC,Hu YM,Meng FY,Li JX,Luo L,Yang JY,Liu P,Yu J

    更新日期:2017-11-01 00:00:00

  • Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.

    abstract::Notifications of infant deaths, assumed to be related to the introduction of new pentavalent DTwP-Hib-HBV childhood vaccines, caused, during 2008-2010 in few Asian countries, temporary interruptions of the respective vaccination programs. The sudden appearance of fatal cases was due to increased awareness/publicity an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.2015.1059759

    authors: Herzog C

    更新日期:2015-01-01 00:00:00

  • PREPS and L-particles: a new approach to virus-like particle vaccines.

    abstract::Conventional virus-like particles are usually composed of a single structural protein which spontaneously assembles into particles. L-particles, a little-known type of virus-like particle, are produced as part of the natural infectious process of many, if not all, alpha-herpesviruses. L-particles lack the nucleocapsid...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.4.427

    authors: Pardoe I,Dargan D

    更新日期:2002-12-01 00:00:00

  • The fundamental link between pneumococcal carriage and disease.

    abstract::Streptococcus pneumoniae (pneumococcus) is a major cause of worldwide mortality and morbidity, and to a large extent is vaccine-preventable. Nasopharyngeal carriage of pneumococcus precedes disease and is the source of pneumococcal spread between people. The use of vaccine effect on carriage as part of the vaccine lic...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.53

    authors: Simell B,Auranen K,Käyhty H,Goldblatt D,Dagan R,O'Brien KL,Pneumococcal Carriage Group.

    更新日期:2012-07-01 00:00:00

  • Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.

    abstract::The need for an affordable, safe and effective HIV vaccine has never been greater. As the immunogenicity of all the vaccine vectors being evaluated currently in human populations is limited, novel vaccine strategies are needed to stimulate the innate immune system, to generate high levels of neutralizing antibodies an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.6.827

    authors: Joseph J,Saubi N,Pezzat E,Gatell JM

    更新日期:2006-12-01 00:00:00

  • Mobilizing and evaluating anticancer T cells: pitfalls and solutions.

    abstract::Immunotherapy is a promising means to fight cancer, prompting a steady increase in clinical trials and correlative laboratory studies in this field. As antitumor T cells play central roles in immunity against malignant diseases, most immunotherapeutic protocols aim to induce and/or strengthen their function. Various t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2013.843456

    authors: Robert-Tissot C,Nguyen LT,Ohashi PS,Speiser DE

    更新日期:2013-11-01 00:00:00

  • Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees.

    abstract::Interview by Jenaid Rees, Commissioning Editor Jeffrey Schlom obtained his PhD from Rutgers University (NJ, USA). After obtaining his PhD, he worked at Columbia University (NY, USA) before moving in 1973 to the National Cancer Institute, National Institutes of Health (MD, USA). Since then he has served as the Chief of...

    journal_title:Expert review of vaccines

    pub_type: 传,历史文章,面试

    doi:10.1586/14760584.2013.836913

    authors: Schlom J

    更新日期:2013-10-01 00:00:00

  • FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.

    abstract::The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.6.833

    authors: Palatnik-de-Sousa CB,Barbosa Ade F,Oliveira SM,Nico D,Bernardo RR,Santos WR,Rodrigues MM,Soares I,Borja-Cabrera GP

    更新日期:2008-08-01 00:00:00

  • Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.

    abstract::Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1176533

    authors: Vici P,Pizzuti L,Mariani L,Zampa G,Santini D,Di Lauro L,Gamucci T,Natoli C,Marchetti P,Barba M,Maugeri-Saccà M,Sergi D,Tomao F,Vizza E,Di Filippo S,Paolini F,Curzio G,Corrado G,Michelotti A,Sanguineti G,Giordano A

    更新日期:2016-10-01 00:00:00

  • ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines.

    abstract::This review describes several enzyme-linked immunosorbent assay (ELISA) techniques proposed to replace the neutralization test for detecting neutralization-relevant antibodies to polioviruses in recipients of inactivated poliovirus vaccine and oral poliovirus vaccine, and for seroepidemiologic studies. Comparisons of ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.2.167

    authors: Ivanov AP,Dragunsky EM

    更新日期:2005-04-01 00:00:00